{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:11:27Z","timestamp":1793923887732,"version":"4.8.0"},"reference-count":65,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:sec id=\"ab-soi250027-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Pharmacogenetics can improve medication-related outcomes by optimizing efficacy and minimizing adverse effects. It is unknown whether the presence of drug-gene interactions (DGIs) at the time of surgery results in adverse outcomes in the postoperative setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi250027-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the association of active DGIs on postsurgical outcomes following vascular surgery procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi250027-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of Veterans Affairs (VA) hospital patients participating in the Million Veteran Program who had a vascular procedure documented in the VA Surgical Quality Improvement Program (VASQIP) from January 1, 2011, to December 31, 2022. Data analysis was performed from June 1, 2023, to October 31, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi250027-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Receipt of drugs impacted by pharmacogenetic variants 30 days prior to and up to 7 days following the vascular surgery procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi250027-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Clinical outcomes collected as part of VASQIP, including length of stay (LOS), 30-day readmission, composite of myocardial infarction, stroke, and myocardial injury after noncardiac surgery, and 30-day postoperative death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi250027-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 10\u202f098 patients (mean [SD] age, 68.8 [8.3] years; 1581 [15.7%] Black [self-reported]; 9884 [97.9%] male), 5020 (49.7%) had a DGI. The most common DGIs included proton pump inhibitors with\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      , statins with\n                      <jats:italic>SLCO1B1<\/jats:italic>\n                      , and clopidogrel with\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      . Compared with 0 DGIs, the presence of 1, 2, or 3 or more DGIs was associated with a longer median (IQR) LOS: with 0 DGIs, 3 (1-6) days vs 1 DGI, 3 (1-7) days (adjusted incidence rate ratio [IRR], 1.12; 95% CI, 1.10-1.14;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001); 2 DGIs, 3 (1-7) days (adjusted IRR, 1.22; 95% CI, 1.19-1.25;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001); and 3 or more DGIs, 4 (2-8) days (adjusted IRR, 1.40; 95% CI, 1.35-1.44;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). The 30-day readmission rate, which was 17.4% among those with 0 DGIs, was not significantly different in those with 1 DGI (17.6%; adjusted odds ratio [aOR], 1.01; 95% CI, 0.90-1.14;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.84) but was significantly higher in those with 2 DGIs (21.2%; aOR, 1.26; 95% CI, 1.08-1.47;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.004) and 3 or more DGIs (25.1%; aOR, 1.61; 95% CI, 1.30-1.99;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). The risk of the composite outcome, which was 3.5% in those with 0 DGIs, was not significantly different in those with 1 DGI (4.1%; aOR, 1.15; 95% CI, 0.91-1.45;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.24) but was significantly higher in those with 2 DGIs (5.7%; aOR, 1.62; 95% CI, 1.22-2.15;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.001) and those with 3 or more DGIs (5.5%; aOR, 1.60; 95% CI, 1.04-2.36;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi250027-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings suggest that patients with DGIs at the time of vascular surgery have increased risk of cardiovascular morbidity, increased readmission, and longer LOS. Further work is needed to determine which DGIs contribute to these outcomes and whether preoperative pharmacogenetic testing has the potential to mitigate these risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamasurg.2025.1503","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:24Z","timestamp":1749034824000},"page":"804","source":"Crossref","is-referenced-by-count":4,"title":["Drug-Gene Interactions and Clinical Outcomes After Vascular Surgery in the Million Veteran Program"],"prefix":"10.1001","volume":"160","author":[{"given":"Sony","family":"Tuteja","sequence":"first","affiliation":[{"name":"Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania"},{"name":"Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Center for Healthcare Outcomes and Implementation Research, Boston, Massachusetts"},{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Ferraro","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Damrauer","sequence":"additional","affiliation":[{"name":"Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania"},{"name":"Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal M. F.","family":"Itani","sequence":"additional","affiliation":[{"name":"Center for Healthcare Outcomes and Implementation Research, Boston, Massachusetts"},{"name":"Department of Surgery, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Surgery, Boston University, Boston, Massachusetts"},{"name":"Department of Surgery, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Voight","sequence":"additional","affiliation":[{"name":"Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania"},{"name":"Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Lynch","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"DuVall","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Strebel","sequence":"additional","affiliation":[{"name":"VA Washington DC Healthcare System, Washington, DC"},{"name":"Office of Research and Development, Veterans Health Administration, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kim","sequence":"additional","affiliation":[{"name":"VA National Artificial Intelligence Institute, Washington, DC"},{"name":"VA Long Beach Healthcare System, Long Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Veterans Affairs Surgical Quality Improvement Program, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Barrett","sequence":"additional","affiliation":[{"name":"VA Portland Health Care System, Portland, Oregon"},{"name":"Department of Medicine, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Million Veteran Program","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Pridgen","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumitra","family":"Muralidhar","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moser","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Deen","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Tsao","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Gaziano","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hauser","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kilbourne","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Matheny","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Oslin","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Voora","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica V.","family":"Brewer","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Brophy","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Cho","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Churby","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Pyarajan","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ringer","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Selva","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahpoor (Alex)","family":"Shayan","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Stephens","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey B.","family":"Whitbourne","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistocles L.","family":"Assimes","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Hung","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kranzler","sequence":"additional","affiliation":[{"name":"for the Million Veteran Program"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7456","key":"soi250027r1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"issue":"15","key":"soi250027r2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"soi250027r3","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/ageing\/afaa188","article-title":"In-hospital adverse drug reactions in older adults; prevalence, presentation and associated drugs\u2014a systematic review and meta-analysis.","volume":"49","author":"Jennings","year":"2020","journal-title":"Age Ageing"},{"issue":"7","key":"soi250027r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055551","article-title":"Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions.","volume":"12","author":"Osanlou","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"soi250027r5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1086-5802(16)31229-3","article-title":"Drug-related morbidity and mortality: updating the cost-of-illness model.","volume":"41","author":"Ernst","year":"2001","journal-title":"J Am Pharm Assoc (Wash)"},{"issue":"9","key":"soi250027r6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1177\/1060028018765159","article-title":"Cost of prescription drug-related morbidity and mortality.","volume":"52","author":"Watanabe","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"8","key":"soi250027r7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial.","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"soi250027r8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis.","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"17","key":"soi250027r9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI.","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"soi250027r10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41397-020-0162-5","article-title":"Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.","volume":"20","author":"Limdi","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"soi250027r12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The Clinical Pharmacogenetics Implementation Consortium: 10 years later.","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"soi250027r13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/jac5.1699","article-title":"How to implement a pharmacogenetics service at your institution.","volume":"5","author":"Cicali","year":"2022","journal-title":"J Am Coll Clin Pharm"},{"issue":"3","key":"soi250027r14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/jac5.1868","article-title":"Establishing a patient-centered, multidisciplinary pharmacogenomics clinic in an academic health system: successes, challenges, and future direction.","volume":"7","author":"Hoffecker","year":"2023","journal-title":"J Am Coll Clin Pharm"},{"issue":"12","key":"soi250027r15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/pgs-2019-0043","article-title":"Implementation of wide-scale pharmacogenetic testing in primary care.","volume":"20","author":"Petry","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"3","key":"soi250027r16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2217\/pgs-2020-0173","article-title":"Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program.","volume":"22","author":"Dong","year":"2021","journal-title":"Pharmacogenomics"},{"issue":"4","key":"soi250027r18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/00000658-199810000-00006","article-title":"The Department of Veterans Affairs\u2019 NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care.","volume":"228","author":"Khuri","year":"1998","journal-title":"Ann Surg"},{"issue":"3","key":"soi250027r19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1001\/jamasurg.2021.6488","article-title":"Comparing Veterans Affairs and private sector perioperative outcomes after noncardiac surgery.","volume":"157","author":"George","year":"2022","journal-title":"JAMA Surg"},{"issue":"1","key":"soi250027r20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/ALN.0000000000000904","article-title":"Evaluation of perioperative medication errors and adverse drug events.","volume":"124","author":"Nanji","year":"2016","journal-title":"Anesthesiology"},{"issue":"4","key":"soi250027r21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/ALN.0b013e31819b5bdc","article-title":"Epidemiology of anesthesia-related mortality in the United States, 1999-2005.","volume":"110","author":"Li","year":"2009","journal-title":"Anesthesiology"},{"key":"soi250027r22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jclinepi.2015.09.016","article-title":"Million Veteran Program: a mega-biobank to study genetic influences on health and disease.","volume":"70","author":"Gaziano","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"soi250027r24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ajhg.2020.03.004","article-title":"Genotyping array design and data quality control in the Million Veteran Program.","volume":"106","author":"Hunter-Zinck","year":"2020","journal-title":"Am J Hum Genet"},{"issue":"2","key":"soi250027r25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41436-018-0054-0","article-title":"Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model.","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"3","key":"soi250027r26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","article-title":"An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine.","volume":"110","author":"Whirl-Carrillo","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"soi250027r29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/ALN.0000000000000113","article-title":"Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes.","volume":"120","author":"Botto","year":"2014","journal-title":"Anesthesiology"},{"issue":"1","key":"soi250027r30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"5","key":"soi250027r31","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.amjsurg.2009.07.025","article-title":"Design and statistical methodology of the National Surgical Quality Improvement Program: why is it what it is?","volume":"198","author":"Henderson","year":"2009","journal-title":"Am J Surg"},{"issue":"8","key":"soi250027r32","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamasurg.2018.0504","article-title":"Practical guide to surgical data sets: Veterans Affairs Surgical Quality Improvement Program (VASQIP).","volume":"153","author":"Massarweh","year":"2018","journal-title":"JAMA Surg"},{"key":"soi250027r33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jss.2023.02.001","article-title":"Does work relative value unit measure surgical complexity for risk adjustment of surgical outcomes?","volume":"287","author":"Dyas","year":"2023","journal-title":"J Surg Res"},{"issue":"2","key":"soi250027r34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/SLA.0000000000002290","article-title":"Myocardial injury after noncardiac surgery (MINS) in vascular surgical patients: a prospective observational cohort study.","volume":"268","author":"Biccard","year":"2018","journal-title":"Ann Surg"},{"issue":"6","key":"soi250027r35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/CRD.0000000000000254","article-title":"Myocardial injury after noncardiac surgery: a systematic review and meta-analysis.","volume":"27","author":"Smilowitz","year":"2019","journal-title":"Cardiol Rev"},{"issue":"4","key":"soi250027r36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cpt.3351","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and beta-blocker therapy.","volume":"116","author":"Duarte","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"soi250027r37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010402","article-title":"Myocardial injury after noncardiac surgery\u2014incidence and predictors from a prospective observational cohort study at an Indian tertiary care centre.","volume":"97","author":"George","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"27","key":"soi250027r38","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA.","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"soi250027r39","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update.","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"soi250027r40","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association.","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"soi250027r41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/1074248416663647","article-title":"Combination use of clopidogrel and proton pump inhibitors increases major adverse cardiovascular events in patients with coronary artery disease: a meta-analysis.","volume":"22","author":"Niu","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"10","key":"soi250027r42","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1111\/cts.13608","article-title":"CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.","volume":"16","author":"Ramste","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"2","key":"soi250027r43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/eurheartj\/ehv456","article-title":"Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study.","volume":"37","author":"Berwanger","year":"2016","journal-title":"Eur Heart J"},{"issue":"17","key":"soi250027r44","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.jacc.2007.06.046","article-title":"Intensity of statin therapy in relation to myocardial ischemia, troponin T release, and clinical cardiac outcome in patients undergoing major vascular surgery.","volume":"50","author":"Feringa","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"soi250027r45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.amjcard.2007.02.093","article-title":"Effect of statin withdrawal on frequency of cardiac events after vascular surgery.","volume":"100","author":"Schouten","year":"2007","journal-title":"Am J Cardiol"},{"key":"soi250027r46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ahj.2016.11.001","article-title":"Atorvastatin for high-risk statin-na\u00efve patients undergoing noncardiac surgery: the Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.","volume":"184","author":"Berwanger","year":"2017","journal-title":"Am Heart J"},{"issue":"5","key":"soi250027r47","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms.","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"soi250027r48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.118.002228","article-title":"Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings.","volume":"11","author":"Peyser","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"12","key":"soi250027r49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.27092","article-title":"Effect of pharmacogenetic testing for statin myopathy risk vs usual care on blood cholesterol: a randomized clinical trial.","volume":"3","author":"Vassy","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"soi250027r50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"soi250027r51","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1161\/01.CIR.0000012530.68333.C8","article-title":"Withdrawal of statins increases event rates in patients with acute coronary syndromes.","volume":"105","author":"Heeschen","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"soi250027r52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/17512433.2014.910111","article-title":"Understanding and preventing drug-drug and drug-gene interactions.","volume":"7","author":"Tannenbaum","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"soi250027r53","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug-drug-gene interactions and adverse drug reactions.","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"soi250027r54","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1517\/14740338.2011.583916","article-title":"A critical evaluation of clinical decision support for the detection of drug-drug interactions.","volume":"10","author":"Smithburger","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"soi250027r55","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3599","article-title":"Implementing pharmacogenomics clinical decision support: a comprehensive tutorial on how to integrate the Epic Genomics module.","author":"Hall","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"soi250027r56","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/ajhp\/zxad111","article-title":"Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar.","volume":"80","author":"Tomcsanyi","year":"2023","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"soi250027r57","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/jamia\/ocz095","article-title":"Medication safety alert fatigue may be reduced via interaction design and clinical role tailoring: a systematic review.","volume":"26","author":"Hussain","year":"2019","journal-title":"J Am Med Inform Assoc"},{"issue":"12","key":"soi250027r58","doi-asserted-by":"publisher","first-page":"844","DOI":"10.2146\/ajhp180149","article-title":"Optimization of clinical pharmacy specialists at Veterans Affairs facilities.","volume":"75","author":"Clancy","year":"2018","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"soi250027r59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ajhp\/55.1.68","article-title":"Characteristics of ambulatory care clinics and pharmacists in Veterans Affairs medical centers. IMPROVE investigators.","volume":"55","author":"Alsuwaidan","year":"1998","journal-title":"Am J Health Syst Pharm"},{"issue":"19","key":"soi250027r60","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1093\/ajhp\/zxae122","article-title":"Integration of a clinical pharmacist practitioner-led pharmacogenomics service in a Veterans Affairs hematology\/oncology clinic.","volume":"81","author":"Dreischmeier","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"18","key":"soi250027r61","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.2146\/ajhp070679","article-title":"Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centers.","volume":"65","author":"Mahmood","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"10374","key":"soi250027r62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"soi250027r63","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.clpt.2005.06.004","article-title":"Ser49Gly of \u00df1-adrenergic receptor is associated with effective \u00df-blocker dose in dilated cardiomyopathy.","volume":"78","author":"Magnusson","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"soi250027r64","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/cpt.2354","article-title":"How to integrate CYP2D6 phenoconversion into clinical pharmacogenetics: a tutorial.","volume":"110","author":"Cicali","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"soi250027r65","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cpt.3314","article-title":"Use of CYP2D6 inhibitors with CYP2D6 opioids: association with emergency department visits for pain.","volume":"116","author":"Nahid","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"soi250027r11","unstructured":"US Food and Drug Administration. Table of pharmacogenetic associations. Accessed March 21, 2022. https:\/\/www.fda.gov\/medical-devices\/precision-medicine\/table-pharmacogenetic-associations"},{"key":"soi250027r17","unstructured":"US Department of Veterans Affairs. Veterans Health Administration: about VA. Accessed April 26, 2024. https:\/\/www.va.gov\/health\/aboutvha.asp"},{"key":"soi250027r23","unstructured":"US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. Accessed October 31, 2023. https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling"},{"key":"soi250027r27","unstructured":"Clinical Pharmacogenetics Implementation Consortium. Accessed October 10, 2023. https:\/\/cpicpgx.org\/"},{"key":"soi250027r28","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) classification. Accessed October 29, 2024. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2835035\/jamasurgery_tuteja_2025_oi_250027_1751386009.94985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:00:33Z","timestamp":1752073233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2835035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2025.1503","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}